Strategic Acquisition Opportunity Following its acquisition by BioAgilytix in October 2021, 360biolabs has expanded its global footprint, presenting an opportunity to promote integrated contract research services to pharmaceutical and biotech clients seeking seamless international clinical trial support.

Specialized Service Range With expertise in advanced bioanalytical assays such as pharmacokinetics, biomarkers, and molecular assays, 360biolabs can cater to drug development companies requiring high-quality, GLP-compliant laboratory services for Phase I-III clinical studies.

Regional Expansion Potential Operating laboratories in Melbourne and Brisbane and partnering internationally, 360biolabs is well-positioned to attract clients in Australia, New Zealand, and Asia-Pacific markets seeking localized, high-standard clinical research support.

Targeting Large Molecule Developers Given its focus on supporting the development of biologics and complex therapeutics, 360biolabs offers tailored solutions for companies engaged in biologics and vaccine development, capitalizing on the growing demand for specialized bioanalytical services.

Partnership and Collaboration Opportunities exist to forge strategic collaborations with contract research organizations and pharmaceutical firms globally, leveraging 360biolabs’ compliance with standards like GLP, GCP, and ISO17025 to access broad clinical trial markets.